ESMO Preceptorship on Immuno-Oncology Zurich 2015

Oncology Meeting Resources

18 Nov - 19 Nov, Zurich, Switzerland

ESMO Preceptorship on Immuno-Oncology

Main learning objectives for the ESMO Preceptorship on Immuno-Oncology Zurich 2015 included understanding the basics of tumour immunology, learning about the essentials of immunotherapies and their applications in cancer medicine, and learning about the status of development and clinical experience of immunotherapy in different tumour types.

Presentations from the Preceptorship are now available here. The use of these presentations is for personal educational purposes only. ESMO thanks the authors for their generosity.

 

Useful Links

Presenter Presentation title Session title
F. Aya Moreno, SP Pembrolizumab After Grade 3 Immuno-Related Colitis With Ipilimumab In Braf-Mutant Melanoma Session 5 Audience cases
G. Buzzatti, IT Nivolumab, An Anti-Pd1 Checkpoint Inhibitor In Lung Adenocarcinoma. A Case Report. Session 5 Audience cases
A.O. Onisim, RO Nivolumab As First-Line Therapy For Stage Iv Squamous-Cell Lung Carcinoma Session 5 Audience cases
M. Saigì Morguì, SP Sustained Response To Immunotherapy In Prostate Cancer Session 5 Audience cases
G. Curigliano, IT Breast Cancer Session 6 Clinical development
L. Kandalaft, CH Immunotherapy For Ovarian Cancer Session 6 Clinical development
B. Bodenmiller, CH Mass Cytometry: A Novel Flow Cytometry Modality To Study Tumor Immunology Session 7 Disease specific talks
D. Speiser, CH Immunomonitoring: “Functional Assessment Of Immune Responses And Identification Of New Antigens” Session 7 Disease specific talks
G. Eisele, CH From The Essentials Of Tumour Immunology To Clinical Application Glioblastoma Session 8 Clinical development
M. Manz, CH Immunotherapy In Hemato-Oncology Session 8 Clinical development
K. Homicsko, CH Management Of Immune Related Adverse Events (irAEs) Session 9 Trial design and management of toxicities
L. Kandalaft, CH Clinical Trial Design And Regulatory Issues Session 9 Trial design and management of toxicities
H. Hammers, US Immunotherapy In Prostate Cancer And Rcc Session 6 Clinical development
A. Curioni, CH Immune Checkpoints Session 2 Essentials in immunotherapies
N. Rufer, CH Cancer Vaccines Session 2 Essentials in immunotherapies